The immunohistochemical profile of Spitz nevi and conventional (non-Spitzoid) melanomas: A baseline study

Modern Pathology

Volumn 23, Issue 9, 2010, Pages 1215-1224

  Garrido Ruiz, María C ^a,e   Requena, Luis ^b   Ortiz, Pablo ^a   Pérez Gómez, Beatriz ^c   Alonso, Soledad R ^d   Rodríguez Peralto, José Luis ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b Jimenez Daz University Hospital   (Spain)

^c CARLOS III INSTITUTE OF HEALTH   (Spain)

^d Guadalajara Hospital   (Spain)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; ISOMERASE; KI 67 ANTIGEN; PROTEIN P16; PROTEIN P21; PROTEIN P53; SURVIVIN; TOPOISOMERASE II ALPHA; UNCLASSIFIED DRUG;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER GROWTH; CELL CYCLE; CELL CYCLE REGULATION; CONTROLLED STUDY; FEMALE; GROWTH CURVE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; JUVENILE MELANOMA; MAJOR CLINICAL STUDY; MALE; MELANOMA; MITOSIS RATE; NON SPITZOID MELANOMA; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY;

EID: 77956269144     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2010.102     Document Type: Article

References (45)

1. Spitz S. Melanomas of childhood. Am J Pathol 1948;24:591-609.
2. Kapur P, Selim MA, Roy LC, et al. Spitz nevi and atypical Spitz nevi/tumors; a histologic and immunohistochemical analysis. Mod Pathol 2005;18:197-204.
3. Piepkorn M. On the nature of histologic observations: the case of the Spitz nevus. J Am Acad Dermatol 1995;32:248-254.
4. Walsh N, Crotty K, Palmer A, et al. Spitz nevus versus spitzoid malignant melanoma: an evaluation of the current distinguishing histopathological criteria. Hum Pathol 1998;29:1105-1112.
5. Barnhill RL. The Spitzoid lesion: the importance of atypical variants and risk assessment. Am J Dermatopathol 2006;28:75-83.
6. Barnhill RL, Piepkorn M, Busam KJ. The Pathology of Melanocytic Nevi and Malignant Melanoma, 2nd edn. Springer Verlag: New York, 2004.
7. Barnhill RL, Argenyi ZB, From L, et al. Aypical Spitz nevi/tumors: lack of consensus for diagnostic, discrimination from melanoma and prediction of outcome. Hum Pathol 1999;30:513-520.
8. Kaleem Z, Lind AC, Humphrey PA, et al. Concurrent Ki-67 and p53 immunolabeling in cutaneous melanocytic neoplasms: an adjunct for recognition of the vertical growth phase in malignant melanoma? Mod Pathol 2000;13:217-222.
9. Alonso SR, Ortiz P, Pollán M, et al. Progression in cutaneous malignant melanoma is associated with distinct expression profiles. A tissue microarray-based study. Am J Pathol 2004;164:193-203.
10. Benjamini Y, Hochberg Y. Controlling the false discovery rate and practical and powerful approach to multiple testing. J R Stat Soc Series B Stat Methodol 1995;57:289-300.
11. Alonso SR, Tracey L, Ortiz P, et al. A high-throughput study in melanoma identifies epithial-mesenchymal transition as a major determinant of metastasis. Cancer Res 2007;67:3450-3460.
12. Darier J, Civatte A. Naevus ou naevo-carcinoma chez un nourisson. Bull Soc Fr Dermatol Syphiligr 1910;21: 61-63.
13. Smith KJ, Barrett TL, Skelton III HG, et al. Spindle and epithelioid cell nevi with atypia and metastasis (malignant Spitz nevus). Am J Surg Pathol 1989;13: 931-933.
14. Ludgate MW, Fullen DR, Lee J, et al. The atypical spitz tumor of uncertain biologic potential. A series of 67 patients from a single institution. Cancer 2009;115: 631-641.
15. Cerroni L. Spitzoid tumors. A matter of perspectives? Am J Dermatopathol 2004;26:1-3.
16. Bastian BC, Wesselmann U, Pinkel D, et al. Molecular cytogenetic analysis of Spitz nevi shows clear differences to melanoma. J Invest Dermatol 1999;113: 1065-1069.
17. Bastian BC, LeBoit PE, Pinkel D. Mutations and copy number increase of HRAS in Spitz nevi with distinctive histopathological features. Am J Pathol 2000;157: 967-972.
18. Bauer J, Bastian BC. DNA copy number changes in the diagnosis of melanocytic tumors. Pathologe 2007;28: 464-473.
19. Harvell JD, Bastian BC, LeBoit PE. Persistent (Recurrent) Spitz Nevi. A histopathologic, immunohistochemical and molecular pathologic study of 22 cases. Am J Surg Pathol 2002;26:654-661.
20. Harvell JD, Kohler S, Zhu S, et al. High-resolution array-based comparative genomic hybridization for distinguishing paraffin-embedded spitz nevi and melanomas. Diagn Mol Pathol 2004;13:22-25.
21. Gerami P, Jewell SS, Morrison LE, et al. Fluorescence in situ hybridization (FISH) as an ancillary diagnostic tool in the diagnosis of melanoma. Am J Surg Pathol 2009;33:1146-1156.
22. Urso C. A new perspective for Spitz tumors? Am J Dermatopathol 2005;27:364-366.
23. Cerroni L. A new perspective for Spitz tumors? Am J Dermatopathol 2005;27:366-367.
24. Howat AJ, Giri DD, Cotton DW, et al. Nucleolar organizer regions in Spitz nevi and malignant melanomas. Cancer 1989;63:474-478.
25. Tu P, Miyauchi S, Miki Y. Proliferative activities in Spitz nevus compared with melanocytic nevus and malignant melanoma using expression of PCNA/cyclin and mitotic rate. Am J Dermatopathol 1993;15: 311-314.
26. Bergman R, Kerner H, Manov L, et al. C-fos protein expression in Spitz nevi, common melanocytic nevi, and malignant melanomas. Am J Dermatopathol 1998;20:262-265.
27. Bergman R, Lurie M, Kerner H, et al. Mode of c-myc protein expression in Spitz nevi, common melanocytic nevi and malignant melanomas. J Cutan Pathol 1997; 24:219-222.
28. Guttman-Yassky E, Bergman R, Manov L, et al. Human telomerase RNA component expression in Spitz nevi, common melanocytic nevi, and malignant melanomas. J Cutan Pathol 2002;29:341-346.
29. Nagasaka T, Lai R, Medeiros LJ, et al. Cyclin D1 overexpression in Spitz nevi: an immunohistochemical study. Am J Dermatopathol 1999;21:115-120.
30. Bergman R, Shemer A, Levy R, et al. Immunohistochemical study of p53 protein expression in Spitz nevi as compared with other melanocytic lesions. Am J Dermatopathol 1995;17:547-550.
31. Sparrow LE, Eldon MJ, English DR, et al. P16 and p21WAF1 protein expression in melanocytic tumors by immunohistochemistry. Am J Dermatopathol 1998;20:255-261.
32. Clarke LE, Fountaine TJ, Hennessy J, et al. Cdc7 expression in melanomas, Spitz tumors and melanocytic nevi. J Cutan Pathol 2009;36:433-438.
33. Hafeez Diwan A, Dang SM, Prieto VG, et al. Lack of maturation with anti-leptin receptor antibody in melanoma but not in nevi. Mod Pathol 2009;22: 103-106.
34. Maldonado JL, Timmerman L, Fridlyand J, et al. Mechanisms of cell cycle arrest in Spitz nevi with constitutive activation of the MAP-kinase pathway. Am J Pathol 2004;164:1783-1787.
35. Michieli P, Chedid M, Lin D, et al. Induction of WAF1/CIP1 by p53-independent pathway. Cancer Res 1994;54:3391-3395.
36. Vidal MJ, Loganzo Jr F, de Oliveira AR, et al. Mutations and defective expression of the WAF1 p21 tumor suppressor gene in malignant melanomas. Melanoma Res 1995;5:243-250.
37. Sauter ER, Yeo UC, Von Stemm A, et al. Cyclin D1 is a candidate oncogene in cutaneous melanoma. Cancer Res 2002;62:3200-3206.
38. Li F, Ambrosini G, Chu EY, et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998;396:580-584.
39. Turley H, Comley M, Houlbrook S, et al. The distribution and expression of the two isoforms of DNA topoisomerase II in normal and neoplastic human tissues. Br J Cancer 1997;75:1340.
40. Mu XC, Tran TA, Ross JS, et al. Topoisomerase II alpha expression in melanocytic nevi and malignant melanoma. J Cutan Pathol 2000;27:242-248.
41. Paradela S, Fonseca E, Pita S, et al. Spitzoid melanoma in children: a clinicopathological study and application of immunohistochemistry as an adjunct diagnostic tool. J Cutan Pathol 2009;36:740-752.
42. Kanter-Lewensohn L, Hedblad MA, Wejde J, et al. Immunohistochemical markers for distinguishing Spitz nevi from malignant melanomas. Mod Pathol 1997;10:917-920.
43. Nasr MR, El-Zammar O. Comparison of pHH3, Ki-67 and survivin immunoreactivity in benign and malignant melanocytic lesions. Am J Dermatopathol 2008; 30:117-122.
44. Koleske AJ, Baltimore D, Lisanti MP. Reduction of caveolin and caveolae in oncogenically transformed cells. Proc Natl Acad Sci USA 1995;92:1381-1385.
45. Dennis JU, Dean NM, Bennett CF, et al. Human melanoma metastasis is inhibited following ex vivo treatment with an antisense oligonucleotide to protein kinase C-a. Cancer Lett 1998;128:65-70.